Kawanishi D T, Reid C L, Morrison E C, Rahimtoola S H
Griffith Laboratories, Department of Medicine, University of Southern California, Los Angeles.
J Am Coll Cardiol. 1992 Feb;19(2):409-17. doi: 10.1016/0735-1097(92)90499-d.
Seventy-four patients with chronic stable mild angina, mild coronary artery disease (83% had one- or two-vessel disease) and normal left ventricular function were studied to measure the response of treadmill exercise performance and painful and silent ischemia in the ambulatory setting to randomly assigned treatment with nifedipine or propranolol and their combination; titration to maximal tolerated dosages was performed in double-blind manner. At 3 months both nifedipine and propranolol reduced the weekly angina rate (p less than 0.05); during treadmill exercise testing, increases (p less than 0.05) were noted in time to angina and total exercise time and decreases in maximal ST depression at the end of exercise. There were no differences between the responses to nifedipine and propranolol and no significant additional changes were seen after another 3 months of therapy. The combination of nifedipine and propranolol reduced the number of patients with angina on exercise treadmill testing from 64% to 38% (p less than 0.05). During ambulatory electrocardiographic monitoring before treatment, there were 1.4 +/- 2.4 (mean +/- SD) episodes/24 h of painful ischemia and a very low silent ischemia frequency: mean 1.1 +/- 2.7 episodes/24 h, mean duration 16 +/- 25 min/24 h. Treatment with propranolol and nifedipine resulted in reduction of episodes and duration of painful and painless ischemia; approximately 77% of patients were free of all ischemic episodes. It is concluded that patients with chronic stable mild angina have a low incidence of silent ischemia. Nifedipine or propranolol alone, titrated to individualized maximally tolerated dosages, are equally effective in long-term control of painful and painless ischemia, anginal episodes and exercise-induced ischemia.(ABSTRACT TRUNCATED AT 250 WORDS)
对74例慢性稳定型轻度心绞痛、轻度冠状动脉疾病(83%为单支或双支血管病变)且左心室功能正常的患者进行了研究,以测量在动态环境下跑步机运动表现以及疼痛性和无症状性心肌缺血对随机分配使用硝苯地平、普萘洛尔及其联合用药治疗的反应;以双盲方式滴定至最大耐受剂量。3个月时,硝苯地平和普萘洛尔均降低了每周心绞痛发作率(p<0.05);在跑步机运动试验期间,心绞痛发作时间和总运动时间增加(p<0.05),运动结束时最大ST段压低减小。硝苯地平和普萘洛尔的反应之间无差异,再治疗3个月后未见显著的额外变化。硝苯地平和普萘洛尔联合用药使运动跑步机试验中出现心绞痛的患者数量从64%降至38%(p<0.05)。治疗前动态心电图监测期间,疼痛性心肌缺血为1.4±2.4(均值±标准差)次/24小时,无症状性心肌缺血频率极低:平均1.1±2.7次/24小时,平均持续时间16±25分钟/24小时。普萘洛尔和硝苯地平治疗使疼痛性和无痛性心肌缺血的发作次数和持续时间减少;约77%的患者无所有缺血发作。结论是慢性稳定型轻度心绞痛患者无症状性心肌缺血的发生率较低。单独使用硝苯地平或普萘洛尔,滴定至个体化最大耐受剂量时,在长期控制疼痛性和无痛性心肌缺血、心绞痛发作及运动诱发的心肌缺血方面同样有效。(摘要截选至250字)